← All trials
NCT06462794
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 28, 2024
- Primary completion
- Feb 28, 2028
- Completion date
- Jun 30, 2029
- First posted
- Jun 17, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 121
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- CytomX TherapeuticsLead sponsor
- CytomX TherapeuticsOfficial
- MerckCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.